Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting ... and renin-angiotensin system-targeting drugs. That puts them at risk of serious ...